



ASX Announcement

25 August 2020

Optiscan Investor Presentation

Optiscan Imaging Ltd (“Optiscan”) is participating in a Finance New Network virtual Investor Event today. Attached is the presentation to be delivered by Optiscan’s Executive Chair, Darren Lurie.

- ends -

This announcement has been authorised for release by the Board of Optiscan.

For investor queries, please contact:

Darren Lurie
Executive Chair
E: dlurie@optiscan.com

About Optiscan

Optiscan is an Australian company that has developed and patented miniaturised confocal microscopes and is a global leader in the development and application of microscopic imaging and related technologies for medical and research markets.

Phone (61 3) 9538 3333

Website www.optiscan.com

PO Box 1066, Mt Waverley MDC VIC 3149 Australia



Optiscan Imaging Ltd (ASX:OIL)

Enabling “Real-time Virtual Biopsy” for
Human Cancer Screening and Surgical
Margin Detection

Notice

This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 25 August 2020.

The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor may require in evaluating a possible investment in OIL or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act 2001 (Cth). No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. Neither OIL, nor any of its officers, employees, officers, agents, consultants or advisers are under any obligation to update any information subsequent to the issue of this presentation.

Future Performance

This presentation contains certain forward-looking statements and unaudited information including regarding the Company's future growth plans, strategies, products, operating performance, milestones, guidance, opinions, estimates, targets, goals, forecasts, earnings and financial position (Forward Looking Statements). The Forward Looking Statements, in this presentation are based on assumptions and contingencies which are subject to change without notice. Actual results and achievements could be significantly different from those expressed in or implied by this presentation. The Forward Looking Statements involve subjective judgements and assumptions as to future events which may or may not be correct and should not be relied upon as an indication or guarantee of future performance. No representation, warranty or assurance (express or implied) is given or made in relation to the achievement of any Forward Looking Statement by any person (including OIL).

Subject to any continuing obligations under applicable law, OIL disclaims any obligation or undertaking to provide any updates or revisions to any Forward Looking Statement in this presentation to reflect any change in expectations in relation to any such Forward Looking Statement or any change in events, conditions or circumstances on which any such statement is based. Nothing in this presentation will create an implication that there has been no change in the affairs of OIL since the date of this presentation.

Past performance

The operating and historical financial information in this presentation not an indication of OIL's views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. Past performance of OIL is not and cannot be relied upon as an indicator of (and provides no guidance as to) future performance.

Notice

Not an offer or financial product advice

This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure document required under the Corporations Act. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. This presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire securities and does not and will not form any part of any contract for acquisition of securities. Each recipient of this presentation should make its own enquiries and investigations regarding all information in this presentation (including, without limitation, the assumptions, uncertainties and contingencies which may affect the future operations of OIL and the impact that different future outcomes may have on OIL).

This presentation has been prepared without taking into account any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. An investment in OIL's shares is subject to known and unknown risks, some of which are beyond the control of OIL. OIL does not guarantee any particular rate of return or the performance of OIL.

Liability

Neither OIL nor any of its officers, employees, officers, agents, consultants or advisers owe any duty (whether in equity, in tort or otherwise) to any investor in connection with this presentation nor do they have any liability (including, without limitation, in negligence) for any loss or damage arising from or in connection with this presentation, except to the extent that such liability may not lawfully be excluded.

To the maximum extent permitted by law, you acknowledge and agree that by taking part in this presentation you will not bring or institute any legal proceedings in contract, in tort, for breach of statutory duty or otherwise against OIL or any of its officers, employees, officers, agents, consultants or advisers in respect of any information provided to it in or in connection with this presentation.

Corporate Snapshot

Board

Darren Lurie – Executive Chair

B.LLB (Hons) and B.COM (Hons)

Former Group CFO and Head of Corporate Development for EduCo International (an investee company of Baring Private Equity Asia). Darren is a former chair and non-executive director of ASX listed Farm Pride Foods Ltd (ASX:FRM).

Dr Philip Currie – Non Executive Director

MBBS (Hons), FRACP, MBA

Dr Currie is a leading cardiologist with more than 35 years experience in medical research, clinical cardiology and business. He completed his cardiology fellowship at the prestigious Mayo Clinic, staff cardiologist at both Mayo Clinic and Cleveland Clinic and was the Director of Echocardiography at Michigan Heart and Vascular Institute.

Graeme Mutton – Non Executive Director

CPA

Graeme is a long-standing shareholder in Optiscan and has a deep understanding of Optiscan's technology and applications. He is a former manager of an accounting practice and successful business owner and operator.

Total Securities on Issue

- 477,778,800 Ordinary Shares
- 25,600,000 unlisted options

Market Capitalisation: ~A\$23 million @4.8c

Operating and Financing Cash Flow Positive for June Quarter 2020



OPTISCAN Introduction - Technology

- Hand-held Confocal Endomicroscope for Medical and Research Imaging**
- World-leading and Patent Protected**
- Real-time “Virtual Biopsy”**
- Reduced and More Targeted Biopsies**
- Capture all Cancer Cells and reduce Tumour Margin in Surgery**

Optiscan FIVE2 Laboratory and InVivage® Clinical Systems



FIVE2 (ViewnVivo) Laboratory System

**4.7 mm
Diameter Tip**



InVivage® Clinical System

Optiscan Applications and Devices

Clinical Applications and Devices:

- Oral Cancer - InVivage[®]
- Breast Cancer - InVivage[®]
- Neurosurgery – CONVIVO[®] (Carl Zeiss Meditec Co-operation)

Pre-clinical Device: FIVE2 (ViewVivo[®])

- Laboratory & Translational Experiments
- Medical Research Facilities and Universities

World Lip & Oral Cavity Cancer Incidence and Mortality

354,864

Total number of new cases in 2018

2%

Of all cancer incidences


177,384

Total deaths in 2018

1.9%

Of all deaths from cancer

	Population	Number
	Asia	227 906
	Europe	61 885
	North America	27 112
	*Latin America and the Caribbean	19 898
	Africa	13 613
	Oceania	4 450
	Total	354 864




Oral Cancer Market Size - United States

71 National Cancer Institute (NCI) Designated Cancer Centers

900 Specialist Cancer Centers

6,146 Total US Hospitals

9,000 Oral and Maxillofacial Surgeons



Oral Market Size - China

□ China: 48 Public Tertiary Dental Hospitals

□ Guangdong Province: 158 Stomatology Departments in General Hospitals, 14 Public and Private Dental Hospitals

Leading Specialist Dental Hospitals:

Name	Location	No. of Chairs	Patient Volume (Out patient annually)
Hospital of Stomatology, PKU	Beijing	569	1,453,000
Hospital of Stomatology, Sichuan University	Chengdu, Sichuan Province	350	750,000
Hospital of Stomatology, The 4 th Military Medical University	Xi'an, Shaanxi Province	270	500,000
Hospital of Stomatology, Wuhan University	Wuhan, Hubei Province	450	960,000
Hospital of Stomatology, Jilin University	Changchun, Jilin Province	195	255,550
Guanghua Hospital of Stomatology, Sun Yat-sen University	Guangzhou, Guangdong Province	326	360,000



Oral Cancer Diagnosis, Survival Rates and Economic Cost

Early Diagnosis



80-90% Five Year
Survival Rate in
Early Diagnosis¹

Late Diagnosis



57% Five Year
Survival Rate in
Late Diagnosis¹

Early Vs Late




2.5x More
Economic
Burden when
Diagnosed Late²

1. Oral Cancer Foundation. <https://oralcancerfoundation.org/>

2. Pollaers, K., et al., The economic burden of oral squamous cell carcinoma in Australia. Journal of Oral Pathology & Medicine, 2019. 48(7): p. 588-594. doi: 10.1111/jop.12907. Epub 2019 Jun 27.

New InVivage® User Interface Designed for Doctors



Squamous epithelial cells and taste bud papillae in tongue (0.5mm x 0.5mm view)

OPTISCAN – Oral Cancer Progress

3 Oral Cancer Studies and Trials

- Received Federal Government ~1m A\$ grant for 150 patient Oral Cancer Study at Melbourne Dental School (includes \$260k payable to Optiscan)
- Trial on-going at the Memorial Sloan Kettering Cancer Centre in New York
- Trial on-going at the Australian Centre for Oral Oncology in Perth

United States FDA Regulatory Approval Activity

- Met with US FDA in January 2020 and obtained feedback on proposed content and format for a 510(k) clearance submission
- Further responses provided by Optiscan to FDA at end of June 2020

Breast Cancer - Most Common Cancer in Women

**2.1
Million**

2.1 million new cases of breast cancer predicted in 2018 (globally) ¹

15%

15% of all new Cancer cases in United States are breast cancer ²

8.5%

8.5% of all new cancer cases in China are breast cancer ³


20-30% of lumpectomy patients currently require repeat surgery with current practice (histopathology analysis) often taking up to 3-4 days post initial surgery.

1. Bray et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68: 394-424. doi:[10.3322/caac.21492](https://doi.org/10.3322/caac.21492)
2. American Cancer Society Estimated 2019 statistics
3. Feng et al. (2019). Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?. Cancer communications (London, England), 39(1), 22. <https://doi.org/10.1186/s40880-019-0368-6>



Optiscan - Breast Cancer Surgery

Intraoperative Assessment of Breast Cancer Surgical Margin

- **Goal**: Assist breast surgeons and pathologists to provide real-time cellular assessment of surgical margin.
 - **Benefits**: Reduce risk of residual tumour, need for repeat surgery, patient emotional distress, costs for patients, hospitals, insurers and the taxpayer by reducing the number of repeat surgeries
- ❑ Discussions underway with leading Melbourne Breast Surgeon and Hospital to arrange Stage 3 of Breast Cancer Trial.



Creation of panoramas: developing a more macro view of the specimen assisting in the CLE and H&E correlation



■ CONVIVO® – Carl Zeiss Meditech (CZM) Co-operation

- ❑ FDA 510(k) clearance and CE Mark obtained
- ❑ “this probably is the most exciting technology that I have seen in my career come through the laboratory.” - Mark C Preul, Neurosurgeon, Barrow Neurosurgical Institute, Arizona, United States.



297K
Brain and CNS
cancer cases every
year worldwide

FIVE2 (Viewnvivo) Distribution Model in China

❑ Multi-distributor model in China with appointment of exclusive distributors in South, West and East China.

- **South and West China:** Guangzhou Yunxing (Purple and Blue)
- **East China:** Biotimes Technology Limited (Green)

❑ Sale of FIVE2 (ViewnVivo) Systems

- **Shanghai (November 2019)**
- **Beijing (August 2020)**
- **Tianjin (August 2020)**




FIVE2 (Viewnivo) Distribution Model for Asia Pacific

Engagement of Dr Joseph Jiafu as a consultant to assist the Company to establish distribution arrangements in Japan, Korea, Singapore and other APAC countries (excluding China).

Dr Joseph Jiafu is a microscopy expert and the former Asia Pacific In Vivo product leader for PerkinElmer Inc.

- Currently the APAC Imaging Director for Magnetic Insight Inc
- Ph.D in Medicine from Tokyo Medical and Dental University, Japan; and
- Master of Public Health (MPH) from National Institute of Public Health of Japan



Outlook

- Commencement of 150 patient Oral Cancer Study at the Melbourne Dental School.
- Commencement of Stage 3 of Breast Cancer Study at leading Melbourne hospital/s
- Increased geographical footprint to deliver additional FIVE2 (ViewnVivo) sales
- Receipt of FDA feedback on InVivage clinical regulatory pathway expected in September

Darren Lurie
Executive Chair
Optiscan Imaging Limited
(ASX:OIL)

dlurie@optiscan.com

www.optiscan.com